Capricor Therapeutics Inc 2025年季度报告

☒Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934for the quarterly period endedMarch 31, 2025 or ☐Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934for the transition period fromto Commission File Number:001-34058 CAPRICOR THERAPEUTICS,INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware(State or other jurisdiction ofincorporation or organization) 10865 Road to the Cure, Suite 150,San Diego,California92121(Address of principal executive offices including zip code) (858)727-1755(Registrant’s telephone number, including area code) Securities registered pursuant to Section12(b)of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)ofthe Securities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrantwas required to file such reports), and (2)has been subject to such filing requirements for the past 90days.☒Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12months (or forsuch shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer,a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,”“accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of the ExchangeAct. Largeacceleratedfiler☐Non-acceleratedfiler☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revised financial accounting standards provided pursuant to Section13(a)ofthe Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).☐Yes☒No As of May 13, 2025, there were45,707,819shares of the registrant’s common stock, par value $0.001 pershare, issued and outstanding. INDEX TO QUARTERLY REPORT ON FORM10-Q Item 1. Financial Statements5Condensed Consolidated Balance Sheets as of March 31, 2025 and December31, 20245Condensed Consolidated Statements of Operations and Comprehensive Loss forthe Three Months Ended March 31, 2025 and 20246Condensed Consolidated Statements of Changes in Stockholders’ Equity for theThree Months Ended March 31, 2025 and 20247Condensed Consolidated Statements of Cash Flows for the Three Months EndedMarch 31, 2025 and 20248Notes to Unaudited Condensed Consolidated Financial Statements9Item 2. Management’s Discussion and Analysis of Financial Condition and Results ofOperations28Item 3. Quantitative and Qualitative Disclosures about Market Risk41Item 4. Controls and Procedures42 PART II. OTHER INFORMATIONItem 1. Legal Proceedings43Item 1A. Risk Factors43Item 2. Unregistered Sales of Equity Securities and Use of Proceeds43Item 3. Defaults Upon Senior Securities43Item 4. Mine Safety Disclosures43Item 5. Other Information43Item 6. Exhibits43Signatures45 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form10-Q contains forward-looking statements within themeaning of Section27A of the Securities Act of 1933, as amended, and Section21E of the SecuritiesExchange Act of 1934, as amended, which statements involve substantial risks and uncertainties.Forward-looking statements generally relate to future events or our future financial or operatingperformance. In some cases, you can identify forward-looking statements because they contain wordssuch as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,”“projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or thenegative of these words or other similar terms or expressions that concern our expectations, strategy,plans or intentions. Forward-looking statements contained in this Quarterly Report on Form10-Qinclude, but are not limited to, statements about: ●how long we expect to maintain liquidity to fund our planned level of operations andour ability to obtain additional funds for our operations;●the development of our drug and vaccine candidates, including when we expect toundertake, initiate and complete clinical trials of our drug and vaccine candidates;●the expectation, plans, projections, initiation, timing, progress and results of ourresearchand development programs,preclinical studies,any clinical trials,compassionate uses,Investigational New Drug filings, Clinical Trial Application filings,New Drug Application filings, Biologics License Application, and other regulatorysubmissions;●regulatory developments involving products and our facilities, including the timing andresults of regulatory meetings and i